Agenda - GVIRF 2021
W8.1 Decision-making and prioritization of vaccines to address public health needs in LMICs
W8.3 The State of Play: Industry vaccine trends from the Access to Medicine Index
W8.2 Prioritization of Vaccines for Global Health
W3.2 Transformative Concepts for Mass Vaccination and Pandemic Response
W2.2 Viral vectored vaccine platform technologies
W9.2 Evidence and Lessons Learned on Social Sciences Analytics around Vaccination
W6.1 Vaccine Development to Access: Opportunities, risks and potential valleys of death
W6.3 Building the concept of WHO Vaccine Preferred Policy Profiles
W1.3 Not enough to go around: vaccine manufacturing for the COVID-19 pandemic
W2.1 Nucleic acid vaccines: Is it all done?
W3.3 Considerations for mass deployment of innovative vaccines in low- and middle-income country immunization programs
W2.4 Universal Influenza Vaccines
P2.1 Current status and future prospects for human immunodeficiency virus (HIV) vaccines
P1.2 Rapid Response Platforms for COVID-19 Vaccine
W4.1 Controlled human malaria infection — tool for accelerating vaccine development
W5.2 Schistosomiasis vaccines, development and role in elimination
P3.2 Impact of COVID-19 on coverage and equity
W5.1 Salmonella typhi vaccines, development and deployment
W6.2 Vaccine development to access: Is there a role for earlier policy consideration?
W7.1 Protection of newborn infants through vaccination
KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience
W3 Innovation in Vaccination
W9 Building and Sustaining Uptake
W4 Controlled Human Infection Models for Vaccine Research and Development
P2 HIV, TB & Malaria Vaccine Update
W9.1 Building and Sustaining Uptake: Summary of the latest evidence and open research questions
W2.3 Adjuvants for use in subunit-based vaccines and global access focus on licensed one
P1 Epidemic and Pandemic Preparedness and Response
W1 Innovations in Vaccine Manufacturing
KN3 Research for Equity
P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030
P3 Shaping the Future: Equitable Access for All
KN2 The Lessons of COVID-19 for Vaccine Development
W5.3 Single-dose HPV Vaccination
W1.2 Vaccine Manufacturing at Lab Scale: A paradigm shift to more affordable vaccines
P1.1 Research during outbreak response: from Ebola to the COVID-19 pandemic
W9.3 Building and Sustaining Uptake: Case study the Philippines
W5.4 Improved vaccines: Novel oral polio vaccine (OPV)
W4.2 Typhoid controlled human infection model
Introduction to GVIRF
P2.2 Update on progress in tuberculosis vaccine development
KN2.2 Innovating from Research to Impact at Scale: the role of the Gavi Alliance
W2 Emerging Platforms
W6 Vaccine Development to Access
W8 Prioritization for Vaccine R&D
P1.3 Rapid (and precise) COVID-19 Vaccine Development Enabled by Prototype Pathogen Preparedness
KN3 Research for Equity - VIDEO
*Meeting Summary: Global Vaccine and Immunization Research Forum, 2021
2:00 - Salmonella typhi, Sushant Sahastrabuddhe, IVI.
20:32 - Schistosomiasis, Robert Bergquist, Geospatial Health.
36:26 - HPV, Aimee Kreimer, NCI/NIH.
52:46 - Novel OPV, Ananda Bandyopadhyay, Bill & Melinda Gates Foundation.
1:08:10 - Block 1 Q&A, Kathleen Neuzil, Robert Bergquist, Aimee Kreimer, Peter Dull.
1:29:56 - Block 2 Q&A, Kathleen Neuzil, Sushant Sahastrabuddhe, Ananda Bandyopadhyay, Peter Dull.